MaaT Pharma's MaaT013 Meets Safety, Feasibility Goal in Phase 2a Melanoma Trial

• MaaT Pharma reported preliminary Phase 2a PICASSO results meeting the safety and feasibility objective for MaaT013 with ipilimumab and nivolumab in metastatic melanoma.
• Response rates were comparable between MaaT013 and placebo, showing no improvement from adding the microbiome therapy to the immunotherapy combination.
• The combination’s safety profile was generally consistent with immunotherapy alone, with no significant difference in serious adverse event rates between treatment groups.
• MaaT013 increased microbiome richness and diversity; exploratory findings suggest patients’ pretreatment microbiome composition may influence response, warranting further investigation.
• Preliminary findings were disclosed through the EU clinical trials database; investigators will present full results at a future scientific congress.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maat Pharma SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20261105503709) on November 06, 2026, and is solely responsible for the information contained therein.